Financials

	2013	2014
Net sales	0.24 0.21 0.2 0.18 0.34 23.52 0.35 2.37 0.93 11.56 0.92 0.9 39.98	3.68 3.23 3 2.76 5.18 354.14 5.26 35.67 13.94 174.11 13.81 13.51 601.99
Net income	-653K -574K -534K -490K -920K -62.93M -934K -6.34M -2.48M -30.94M -2.45M -2.4M -107M	-1.31M -1.15M -1.07M -983K -1.85M -126M -1.88M -12.73M -4.97M -62.12M -4.93M -4.82M -215M
Net Debt	1.33M 1.17M 1.08M 994K 1.87M 128M 1.9M 12.87M 5.03M 62.82M 4.98M 4.87M 217M	1.89M 1.66M 1.55M 1.42M 2.67M 182M 2.71M 18.38M 7.18M 89.71M 7.11M 6.96M 310M

* Estimated data More financial data

Company Profile

Oncologix Tech, Inc. is a shell company. The Company is a non-operating holding Company. The Company has no operations. The Company seeks to acquire an operating company via reverse merger.

Employees

Sector

Investment Holding Companies

More about the company

Market Cap	306K 269K 250K 229K 431K 29.48M 438K 2.97M 1.16M 14.49M 1.15M 1.12M 50.11M	P/E 2013	-1.03x	P/E 2014	-0.47x
Enterprise Value	2.2M 1.93M 1.8M 1.65M 3.1M 212M 3.15M 21.35M 8.34M 104M 8.26M 8.08M 360M	EV / Sales 2013	8,716,069x	EV / Sales 2014	721,342x
Free-Float	99%	Yield 2013 *	-	Yield 2014	-

24-11-28	Reliance's US unit buys $12 million stake in helium explorer Wavetech Helium	RE
22-05-01	DNAGO.Ai entered into a definitive business combination agreement to acquire Oncologix Tech, Inc. in a reverse merger transaction.	CI
16-12-02	Oncologix Tech, Inc. Announces Management Changes	CI
16-08-30	Oncologix Tech, Inc. announced that it expects to receive $10 million in funding from Diversified Innovative Marketing Enterprises Limited	CI
16-06-24	Oncologix Tech, Inc. Announces Board Changes	CI
15-07-29	Oncologix Tech, Inc. Appoints Nikole Jessie as Director of Marketing and Public Relations	CI
15-07-21	Oncologix Tech Inc. Reports Revenue Results Third Quarter and Nine Months Ending May 31, 2015	CI
15-07-21	Oncologix Tech Eyes Acquisitions	CI
15-04-14	Oncologix Tech, Inc. Announces Earnings Results for the Second Quarter and Revenue Results for the Six Months Ended February 28, 2015; Provides Earnings Guidance for the Third Quarter and Full Year of Fiscal 2015	CI
15-04-14	Oncologix Seeks Acquisitions	CI
15-01-16	Oncologix Tech, Inc. Reports Earnings Results for the First Quarter Ending November 30, 2014; Provides Earnings Guidance for Second Quarter of 2015	CI
14-12-30	OCLG Mulls Acquisitions	CI
14-10-07	Oncologix Tech Mulls Acquisitions	CI

22-05-02	DNAGO and Oncologix Tech, Inc. Announce Agreement for Business Combination to Create Publicly Listed Company Focused on Providing clinical genetic testing on all 20,000+ genes encompassing 7,000+ rare genetic diseases at affordable price	GL
22-05-02	DNAGO and Oncologix Tech, Inc. Announce Agreement for Business Combination to Create Publicly Listed Company Focused on Providing clinical genetic testing on all 20,000+ genes encompassing 7,000+ rare genetic diseases at affordable price	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCOLOGIX TECH, INC.	+16.67%	+16.67%	-	-	166K
BOXABL INC.	-23.85%	-26.51%	-38.17%	-	14.73B
CHURCHILL CAPITAL CORP XI	-5.00%	-5.46%	-	-	762M
CENTIEL AG	+1.22%	+19.06%	+298.80%	-66.05%	661M
DEEP FISSION, INC.	-3.84%	-3.66%	-	-	619M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.10%	+0.20%	-	-	643M
CHURCHILL CAPITAL CORP XII	+0.65%	+1.02%	-	-	605M
CANTOR EQUITY PARTNERS IV, INC.	+0.38%	+0.62%	-	-	600M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.16%	+0.15%	-	-	597M
Average	-1.50%	-2.74%	+130.31%	-66.05%	2.4B
Weighted average by Cap.	-18.52%	-25.55%	-23.70%	-66.05%

Oncologix Tech, Inc. Stock Other OTC

Stocks

OCLG

US68230M2098

Investment Holding Companies

Valuation: Oncologix Tech, Inc.

Latest news : Oncologix Tech, Inc.

Press Releases: Oncologix Tech, Inc.

Quotes and Performance

Managers and Directors: Oncologix Tech, Inc.

Shell Companies

Financials

Company Profile